BINDTI: A bi-directional Intention network for drug-target interaction identification based on attention mechanisms.

The identification of drug-target interactions (DTIs) is an essential step in drug discovery. In vitro experimental methods are expensive, laborious, and time-consuming. Deep learning has witnessed promising progress in DTI prediction. However, how to precisely represent drug and protein features is a major challenge for DTI prediction. Here, we developed an end-to-end DTI identification framework called BINDTI based on bi-directional Intention network. First, drug features are encoded with graph convolutional networks based on its 2D molecular graph obtained by its SMILES string. Next, protein features are encoded based on its amino acid sequence through a mixed model called ACmix, which integrates self-attention mechanism and convolution. Third, drug and target features are fused through bi-directional Intention network, which combines Intention and multi-head attention. Finally, unknown drug-target (DT) pairs are classified through multilayer perceptron based on the fused DT features. The results demonstrate that BINDTI greatly outperformed four baseline methods (i.e., CPI-GNN, TransfomerCPI, MolTrans, and IIFDTI) on the BindingDB, BioSNAP, DrugBank, and Human datasets. More importantly, it was more appropriate to predict new DTIs than the four baseline methods on imbalanced datasets. Ablation experimental results elucidated that both bi-directional Intention and ACmix could greatly advance DTI prediction. The fused feature visualization and case studies manifested that the predicted results by BINDTI were basically consistent with the true ones. We anticipate that the proposed BINDTI framework can find new low-cost drug candidates, improve drugs' virtual screening, and further facilitate drug repositioning as well as drug discovery. BINDTI is publicly available at https://github.com/plhhnu/BINDTI.